Experiments with the bone marrow of non-myeloma patients demonstrated a tendency of greater CD38 (+) cell capture by AluSp and MER11C compared to controls or PC transposon sequences, with the trend disappearing in CD38 (–) cells. Here, CD38 is linked to plasma cell myeloma.